Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516522 | 0.78 | SMYD2 (0.41) | AGTR2RIPK1CYP3A4CTSKP2RX7 | |
| SCHEMBL4516524 | 0.78 | SMYD2 (0.41) | AGTR2RIPK1CYP3A4CTSKP2RX7 | |
| SCHEMBL4330114 | 0.74 | LMNA (0.41) | AGTR2KMT2ACTSKP2RX7CTSL | |
| SCHEMBL21802089 | 0.72 | FKBP1A (0.35) | — | |
| SCHEMBL2590322 | 0.68 | SMYD2 (0.40) | RIPK1CYP3A4 | |
| SCHEMBL2347597 | 0.68 | KLK7 (0.41) | L3MBTL1 | |
| SCHEMBL2352753 | 0.68 | KLK7 (0.41) | L3MBTL1 | |
| SCHEMBL1274529 | 0.64 | ALDH1A1 (0.42) | RIPK1L3MBTL1 | |
| SCHEMBL2348913 | 0.62 | KLK7 (0.42) | CTSKCTSLCTSS | |
| SCHEMBL1274502 | 0.62 | RIPK1 (0.46) | KMT2ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | AGTR2 188/4885KMT2A 2733/4885RIPK1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.